US › Healthcare

Genelux Corporation Common Stock (GNLX)

US · Healthcare · Biotechnology

$2.82-5.37%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Revenue YoY
-100.0%
Net profit
$-7.1M
Profit YoY
+4.9%
EPS
$-0.20
EPS estimate
$-0.20

EPS came in at -0.20 against a street estimate of -0.20 — a beat of 0.0%.

Key statistics

Market cap
$131.8M
Forward P/E
0.0
P/B
5.77
Book value
$0.52
EPS (TTM)
$-0.85
52-week high
$8.54
52-week low
$2.29
50-day MA
$2.95
200-day MA
$3.54
Beta
0.57

Analyst view

Analysts rate Genelux Corporation Common Stock a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $17.50.

Shareholding

Insiders
13.12%
Institutions
31.10%

Largest institutional holders

FundStake
WOODWARD DIVERSIFIED CAPITAL, LLC4.72%
Vanguard Capital Management, LLC3.78%
Vanguard Group Inc3.46%
Bleichroeder LP3.08%
Geode Capital Management, LLC1.01%
BlackRock Inc0.91%
Bank of America Corp0.72%
F.L.Putnam Investment Management0.63%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Genelux Corporation Common Stock — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.